|
|
Volumn 3, Issue 10, 2006, Pages 523-
|
|
The dilemma and promise of cancer chemoprevention
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
FINASTERIDE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
RALOXIFENE;
TAMOXIFEN;
ANTIESTROGEN;
BLEEDING;
BREAST CANCER;
CANCER;
CANCER RISK;
CARDIOVASCULAR DISEASE;
CHEMOPROPHYLAXIS;
CLINICAL TRIAL;
EDITORIAL;
HIGH RISK PATIENT;
HOT FLUSH;
HUMAN;
INDIVIDUALIZATION;
PRIORITY JOURNAL;
PROSTATE CANCER;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
SEXUAL DYSFUNCTION;
TREATMENT PLANNING;
VAGINA DISCHARGE;
BREAST TUMOR;
NEOPLASM;
RISK FACTOR;
BREAST NEOPLASMS;
CHEMOPREVENTION;
ESTROGEN ANTAGONISTS;
HUMANS;
NEOPLASMS;
RALOXIFENE;
RISK FACTORS;
|
|
EID: 33750575970
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0609 Document Type: Editorial |
|
Times cited : (28)
|
|
References (0)
|
